Abstract
Lysozyme nephropathy is a frequently unrecognized cause of renal disease in chronic myelomonocytic leukemia and may serve as a novel indication for treatment in this patient population. We demonstrate that in newly diagnosed CMML patients, plasma lysozyme levels are positively correlated with both absolute monocyte count and serum creatinine. Lysozyme is a bacteriolytic enzyme detectable in monocytes. Lysozyme is reabsorbed by renal proximal tubule cells until concentrations exceed 45 μg/mL and urinary excretion is observed. 1 Increased serum and urine lysozyme are seen in diseases characterized by monocytic proliferation, including myeloid leukemia. 1 We measured plasma lysozyme in CMML patients at diagnosis (N = 18), on therapy with hypomethylating agents (N = 10), and in healthy controls (N = 6). Median concentrations were highest at diagnosis (7.5 µg/mL) and correlated with monocyte count and serum creatinine (Figure 1C,D) . Treatment reduced concentrations (1.59 µg/mL), without reaching those of controls (0.68 µg/mL).
Renal impairment in CMML may reflect age-related comorbidities. However, intravenous lysozyme causes tubular damage in rats, arguing that monocyte-derived lysozyme could cause renal injury in CMML that is amenable to reversal with cytoreduction.
